Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in High-risk Nasopharyngeal Carcinoma
NCT04557020Phase 3Recruiting
- Start
- Dec 2020
- Primary completion
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of toripalimab in nasopharyngeal carcinoma (NPC) (2 arms). Primary endpoint: Progression-Free Survival at 3 years. Started Dec 2020; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04557020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557020.